Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.2% |
| 2 | Technology | 14.19% |
| 3 | Financials | 12.33% |
| 4 | Consumer Staples | 10.22% |
| 5 | Industrials | 9.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
VDTH
2001
DELISTED
Videocon d2h Limited
VDTH
| $3.13M | ﹤0.01% |
321,800
+2,400
| +0.8% | +$25.1K |
|
2002
Allegion
ALLE
$14B
| $3.13M | ﹤0.01% |
38,600
-246,400
| -86% | -$19.3M |
|
|
WSTL
2003
DELISTED
Westell Technologies Inc
WSTL
| $3.13M | ﹤0.01% |
998,658
+55,301
| +6% | +$153K |
|
2004
Genie Energy
GNE
$383M
| $3.11M | ﹤0.01% |
408,597
+25,721
| +7% | +$197K |
|
|
ITCI
2005
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $3.11M | ﹤0.01% |
250,600
-25,400
| -9% | -$295K |
|
|
CXP
2006
DELISTED
COLUMBIA PROPERTY TRUST, INC.
CXP
| $3.11M | ﹤0.01% |
138,900
-96,749
| -41% | -$2.15M |
|
|
VG
2007
DELISTED
Vonage Holdings Corporation
VG
| $3.11M | ﹤0.01% |
475,326
-351,000
| -42% | -$2.34M |
|
2008
Air T
AIRT
$79.2M
| $3.11M | ﹤0.01% |
219,900
-1,800
| -0.8% | -$23.5K |
|
|
SCS
2009
DELISTED
Steelcase
SCS
| $3.11M | ﹤0.01% |
+222,000
| New | +$3.66M |
|
2010
AllianceBernstein
AB
$3.41B
| $3.09M | ﹤0.01% |
130,700
-88,625
| -40% | -$1.99M |
|
|
RFP
2011
DELISTED
Resolute Forest Products Inc.
RFP
| $3.07M | ﹤0.01% |
697,600
-168,000
| -19% | -$833K |
|
2012
Primis Financial Corp
FRST
$413M
| $3.06M | ﹤0.01% |
174,142
+14,844
| +9% | +$257K |
|
2013
Western Midstream Partners
WES
$20.2B
| $3.06M | ﹤0.01% |
71,252
+26,800
| +60% | +$1.18M |
|
2014
China Yuchai International
CYD
$1.7B
| $3.06M | ﹤0.01% |
168,114
-149,800
| -47% | -$2.69M |
|
|
LXFT
2015
DELISTED
Luxoft Holding, Inc.
LXFT
| $3.06M | ﹤0.01% |
50,293
+41,100
| +447% | +$2.58M |
|
|
STCN
2016
DELISTED
Steel Connect, Inc. Common Stock
STCN
| $3.06M | ﹤0.01% |
191,522
+2,325
| +1% | +$34.8K |
|
|
EPZM
2017
DELISTED
Epizyme, Inc
EPZM
| $3.03M | ﹤0.01% |
200,788
+85,600
| +74% | +$1.29M |
|
2018
DHT Holdings
DHT
$3.14B
| $3.03M | ﹤0.01% |
730,300
+586,000
| +406% | +$2.55M |
|
|
GNBC
2019
DELISTED
Green Bancorp, Inc
GNBC
| $3.03M | ﹤0.01% |
156,200
-54,314
| -26% | -$1M |
|
2020
Diamondback Energy
FANG
$56.7B
| $3.03M | ﹤0.01% |
+34,100
| New | +$3.31M |
|
|
DGAS
2021
DELISTED
Delta Natural Gas Co Inc
DGAS
| $3.03M | ﹤0.01% |
99,300
+26,400
| +36% | +$798K |
|
|
MGIC
2022
DELISTED
Magic Software Enterprises
MGIC
| $3.02M | ﹤0.01% |
380,352
+40,200
| +12% | +$319K |
|
2023
Modine Manufacturing
MOD
$11.1B
| $3.02M | ﹤0.01% |
182,544
+109,044
| +148% | +$1.49M |
|
2024
Paylocity
PCTY
$7.87B
| $3.02M | ﹤0.01% |
+66,800
| New | +$2.91M |
|
2025
Movado Group
MOV
$803M
| $3.02M | ﹤0.01% |
119,500
+27,600
| +30% | +$637K |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.